Marinus Pharmaceuticals, Inc (NASDAQ:MRNS) Receives $21 11 Average PT from Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued research reports about the company. Robert W. Baird dropped their price objective on Marinus Pharmaceuticals from $24.00 to […]
Royal Bank of Canada Cuts Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $20 00 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) had its price target lowered by Truist Financial from $42.00 to $32.00 in a research report released on Friday morning, Marketbeat reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other brokerages also recently weighed in on MRNS. Oppenheimer downgraded shares of Marinus Pharmaceuticals […]
Tekla Capital Management LLC acquired a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 456,780 shares of the biopharmaceutical company’s stock, valued at approximately $3,152,000. Tekla Capital Management LLC owned approximately […]